Crescent Biopharma gains rights to a Kelun-Biotech antibody drug conjugate it plans to test in combination with its lead cancer drug, a bispecific antibody designed to block PD-1 and VEGF. Separately, Crescent raised $185 million in a private placement to support its clinical trial plans.
The post Crescent Bio Expands Its Cancer Drug Combo Ambitions With New Kelun-Biotech Alliance appeared first on MedCity News.
